researchers analyzed markers of ovarian reserve in 20 premenopausal breast cancer patients who had been treated with adjuvant chemotherapy, who were one or more years out from their diagnosis, and who had no evidence of recurrence. The evaluation involved five tests conducted two, three or four days after a menstrual cycle to assess the ovaries’ physical condition, hormone levels and a compound involved in the menstrual cycle.
In four of the five tests, the breast cancer survivors had a worse ovarian reserve than did the control group.
Important implications for women who are interested in having children after receiving chemotherapy," said Ann Partridge, MD, MPH, of Dana-Farber, who led the study. "Studies that track breast cancer survivors following treatment are needed to determine the predictive value of these tests for pregnancy."